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Abstract:  
Introduction: Oedema extension distance (EED) is a derived parameter that may reduce 
sample size requirements to demonstrate reduction in perihaematomal oedema in early-phase 
acute intracerebral haemorrhage (ICH) trials. We aimed to identify baseline predictors of EED 
and its association with clinical outcomes. 
Patients and methods: Using VISTA-ICH, INTERACT1 and MISTIE-II datasets, we 
calculated EED at baseline and at 72 hours measured using computed tomography. Using linear 
regression, we tested for associations between baseline characteristics and EED at 72 h.  
Ordinal regression (underlying assumptions validated) was used to test for associations 
between EED at baseline, 72h and EED change between baseline and 72 h, and modified 
Rankin scale (mRS) scores at 90 days, adjusted for baseline and 72 h prognostic factors.  
Results: There were 1,028 ICH cases with outcome data for analyses. Mean (standard 
deviation, SD) EED at 72 h was 0.54 (0.26) cm, and mean EED difference from baseline 
(EED72-0) was 0.24 (0.18) cm. EED at 72 h was greater with increasing baseline haematoma 
volume and baseline EED. Increasing age, lobar haemorrhage and IVH were independently 
associated with EED72-0. In multifactorial ordinal regression analysis, EED72-0 was associated 
with worse mRS scores at 90 days (OR 1.96, 95% confidence interval (CI) 1.00 to 3.82).  
Conclusions: Increase in EED over 72 h is independently associated with decreasing 
functional outcome at 90 days. EED may be a useful surrogate outcome measure in early phase 
trials of anti-oedema or anti-inflammatory treatments in ICH.   
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Introduction 
Perihaematomal oedema (PHE) develops rapidly and increases over several days following 
acute spontaneous intracerebral haemorrhage (ICH) and is proposed to reach maximal volume 
by two weeks(1). The additional mass effect of PHE contributes to early neurological 
deterioration and poor outcome(2,3). In addition, PHE may be a marker of secondary injury 
and a potential therapeutic target in ICH(4). A key-mediator of PHE is the innate immune 
response within the brain, characterised by the activation of resident microglia by damage-
associated molecular patterns, infiltration of peripheral immune cells, and the production of 
inflammatory mediators(5). These inflammatory mechanisms orchestrate tissue damage and 
blood–brain barrier breakdown, playing a key role in the development of PHE(6).  
PHE has been widely used as the main outcome measure in pre-clinical ICH studies targeting 
secondary injury and can be efficiently and reliably measured in both the experimental and 
clinical settings(7–9). We have recently described a novel parameter, the oedema extension 
distance (EED), which has been employed by other groups(10,11). It is relatively less 
dependent on haematoma volume and may reduce the sample size required in proof-of-concept 
trials by around 75% when compared to absolute or relative PHE volume(12). Understanding 
the baseline determinants of EED and its association with clinical outcomes is required to 
establish the utility of EED as a surrogate outcome measure in ICH clinical trials.  
In this study, we aimed to evaluate the EED in a large sample of ICH patients (taken from the 
Virtual International Stroke Trials Archive [VISTA](13), the first Intensive Blood Pressure 
Reduction in Acute Cerebral Hemorrhage Trial [INTERACT1](14), and the Minimally 
Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation II [MISTIE II] trial(15)), 
to test for associations between EED, baseline clinical characteristics and clinical outcome.    
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Patients and methods 
We conducted a retrospective analysis of prospectively collected data from three sources: 
VISTA(13), INTERACT1(14) and MISTIE-II(15). Patients aged ≥18 years old with a 
supratentorial ICH were eligible for inclusion in our study. Those with high premorbid 
disability were excluded from the trials from which the datasets are derived. Ethical approval 
was not required for the re-use of these existing, anonymised clinical trial datasets.  
Variables included baseline clinical characteristics (age, sex, hypertension, smoking, diabetes 
mellitus, hypercholesterolaemia, atrial fibrillation, past history of stroke or transient ischaemic 
attack [TIA], smoking status, baseline blood pressure, and neurological impairment based on 
scores on the National Institutes of Health Stroke Scale [NIHSS]), medication at baseline 
(antiplatelet agent[s], anticoagulants, and lipid lowering/statin use), imaging parameters 
(baseline and 72 hour haematoma and oedema volumes, haematoma location, presence of 
intraventricular haemorrhage [IVH]) and outcome data at 90 days.  
All datasets used equivalent techniques to calculate PHE.  As described in Yang et al (16), 
PHE volumes were calculated independently by two trained neurologists, blind to clinical data, 
treatment, and date and sequence of scan, using computer-assisted multi-slice planimetric and 
voxel threshold techniques. A semi-automated threshold-based approach (range 5-33 
Hounsfield Units) was applied with adjustment to identify regions of PHE to estimate volumes 
(cm3) from slice thickness separate to boundaries of blood. Inter-reader reliability was tested 
with re-analysis after 30% and 60% of the scans were read by both readers to assess for 
drift(16).  
The EED was calculated from the haematoma and PHE volumes, as outlined elsewhere(12) 
(Figure 1) at baseline (EED0) and 72 h (EED72), and these were used to calculate change from 
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baseline to 72 h (EED72-0). The relationship between PHE volume and EED is described by the 
equation below:  
𝑃𝑃𝑃𝑃𝑃𝑃 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 = 43𝜋𝜋(3𝑟𝑟ℎ2𝑟𝑟𝑒𝑒𝑒𝑒𝑒𝑒 + 3𝑟𝑟ℎ𝑟𝑟𝑒𝑒𝑒𝑒𝑒𝑒2 + 𝑟𝑟𝑒𝑒𝑒𝑒𝑒𝑒3 ) 
Where rh is the radius of the haematoma and reed is the EED.  
Statistical methodology 
Summary statistics were used to inform sample size calculations for trials with EED as an 
endpoint. Pearson correlation coefficients were used to test for correlations between 
perihaematomal oedema and EED with haematoma volumes at baseline and 72 hours with 
visual representation using box plots, a comparison of correlation coefficients drawn from the 
same sample was performed. Multifactorial linear regression was used to test for associations 
between EED72-0 and baseline clinical and imaging characteristics. Ordinal regression 
models were used to determine independent associations of EED and outcome (90-
day mRS scores), with EED0, EED72, and EED72-0 considered in separate models. 
Backward elimination was used to select the final model for linear and ordinal 
regression, with variables being removed manually after inspection of model fit. A Cox 
regression model was also used to examine mortality over 90 days. Data are reported 
with odds ratios (OR) or hazard ratios (HR), as appropriate, with 95% confidence 
intervals (CI). A sensitivity analysis excluding those patients with acute neurosurgical 
intervention was performed. All analyses were undertaken using Stata Statistical Software: 
Release 14 (StataCorp 2015).  
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Results 
Of a total of 1,373 ICH patients in the pooled dataset (286 INTERACT1, 987 VISTA and 100 
MISTIE-II); 50 were excluded due to infratentorial ICH, 71 as their 72 h follow-up scan was 
performed <48 hours or >96 hours from ictus and 224 due to incomplete data (see Supplemental 
Figure I for details). Thus, 1,028 ICH patients comprised the final study population. Table 1 
shows that patients in the MISTIE-II dataset had larger haematoma and oedema volumes, a 
higher proportion of vascular risk factors (hypertension and hypercholesterolaemia), and a 
higher proportion of lobar ICH and IVH than those in the other datasets.  
Overall, mean (SD) EED0 and EED72 were 0.30 cm (0.14) and 0.54 cm (0.26), respectively, 
and mean EED72-0 was 0.24 cm (0.18). The relationship between EED0 and EED72 is 
demonstrated by scatterplot in Supplemental Figure II. Table 2 indicates the sample sizes 
required to detect reductions in the various PHE volume parameters. For example, to detect a 
10% effect size with 90% power, 3179, 2673 and 1182 ICH patients are needed for the different 
endpoints of difference from baseline to 72 hours in PHE volume, relative PHE volume, and 
EED, respectively. At median values for haematoma volume and EED, a given percentage 
reduction in EED is expected to give rise to a similar reduction in PHE volume using the model 
described in Figure 1. 
Figure 2 demonstrates a positive correlation between (a) baseline (r= 0.78; p< 0.001) and (b) 
72 h PHE and haematoma volumes (r= 0.80; p<0.001), confirming that PHE volume is strongly 
influenced by haematoma size. In contrast, EED is much less strongly correlated with 
haematoma volume at baseline (r= 0.35; p<0.001) and 72 hours (r= 0.30; p< 0.001).  A 
comparison of the respective correlation coefficients demonstrated significant difference at 
both baseline and 72 hours (p <0.001). Table 3 shows results of a multivariable linear 
regression model used to identify factors associated with EED72-0.  Larger baseline haematoma 
volume was associated with higher EED72-0 (p <0.001), whereas increasing age (p <0.001), 
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lobar location [vs. deep] (p = 0.018), and presence of IVH [vs. not] (p= 0.003) were associated 
with lower EED72-0.  Table 4 shows the results of ordinal regression analysis; larger EED72-0 
(OR 1.96, 95% CI 1.00 to 3.82), presence of IVH, diabetes mellitus, prior use of antiplatelets 
and anticoagulation and 72 hour haematoma volume were independently associated with a poor 
90 day outcome (mRS score 3-6). Lobar haemorrhage location and male sex were predictive 
of a good 90 day outcome (mRS score 0-2). At 90 days 128 (12.5%) patients had died. EED72-
0 was not associated with death by 90 days (HR 2.21, 95% CI 0.90 to 5.47) (Supplementary 
Table I).  
Of the 1,028 patients, 82 (8.0%) underwent acute neurosurgical intervention (41 VISTA and 
41 MISIE-II). Of the 41 VISTA patients, 26 (63.4%) underwent ventricular drainage, 2 (4.9%) 
underwent haematoma evacuation, 5 (12.2%) had craniotomies and in 8 (19.5%), the procedure 
details were unavailable. The MISTIE-II patients who had undergone neurosurgical 
intervention were in the minimally invasive surgery treatment arm of the trial. A multivariable 
ordinal regression sensitivity analysis was performed excluding patients that underwent acute 
neurosurgery and larger EED72-0 was associated with 90 day outcome (OR 1.95, 95% CI 0.97- 
3.92) with a similar OR point estimate, but it was no longer statistically significant (p=0.06) 
(Supplementary Table II). 
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Discussion 
Our analysis of a large dataset of over 1,000 ICH patients has shown that EED72-0, as a derived 
parameter, can markedly reduce the sample size required in early-phase ICH clinical trials 
targeting PHE, as compared with conventional measures of absolute or relative PHE volumes. 
We show that higher EED72-0 is associated with higher baseline haematoma volume, while a 
lower EED72-0 was associated with advancing age, lobar location and IVH.  Furthermore, 
EED72-0 was independently associated with a worse 90-day outcome, as measured by mRS.  
As haematoma and PHE volumes are closely correlated, PHE is highly variable and 
necessitates large sample sizes for clinical trials with oedema as an outcome measure.  Relative 
PHE volume has been considered as a means of reducing the variability introduced by the 
correlation between haematoma and oedema volumes, but is typically disproportionately large 
for smaller haematoma volumes, and thus an unsuitable parameter for clinical trials(8).  PHE 
is strongly influenced by the intensity of the parenchymal inflammatory response, which 
diffuses in a linear fashion from the haematoma border.  Conversely, EED is relatively less 
dependent on haematoma volume and likely to be more representative of the 
pathophysiological processes related to PHE than total PHE volume(17). 
In performing a sensitivity analysis by excluding patients with acute neurosurgical 
intervention, the p-value for the association between EED72-0 and 90-day mRS increased from 
0.049 to 0.06. The majority of neurosurgical patients in VISTA had ventricular drainage only 
(26/ 41; 63.4%), which would not be expected to significantly alter the PHE. Patients in 
MISTIE were randomized to either undergo tPA-augmented minimally invasive surgery to 
evacuate the haematoma or standard medical care. Our analysis demonstrates a clear 
correlation between haematoma volume and PHE volume, suggesting that a surgical reduction 
in haematoma volume will also reduce PHE volume, which was confirmed in MISTIE-II(9). 
However, given that EED is relatively less dependent on haematoma volume (unlike PHE 
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volume) we would not expect EED to be reduced in patients undergoing haematoma 
evacuation, relative to non-surgical patients. Further analysis of our dataset confirms this, with 
no difference in EED72-0 between surgical and non-surgical patients, either in the whole 
combined dataset (surgical mean EED72-0 0.24cm [SD 0.20cm] vs. non-surgical mean EED72-0 
0.24cm [0.18cm]; T-test p= 0.86) or within the MISTIE II dataset alone (surgical 0.16cm 
[0.16cm] vs. non-surgical 0.14cm [0.10cm]; p= 0.44). The slight increase in the p-value from 
0.049 to 0.06 on excluding surgical cases is thus likely to be related to reduced power (a type 
II statistical error), rather than heterogeneity in the association between EED72-0 and 90-day 
mRS by whether or not neurosurgery was performed. 
We have identified larger haematoma volume as predictors of EED72-0. Older age, lobar (vs. 
deep) haemorrhage location and IVH were predictors of smaller EED72-0. Older age is an 
independent predictor of poor outcome after ICH and is used in clinical grading scales(18).  
However, this might be due to any number of pathophysiological mechanisms, such as 
impaired coagulation cascade, inflammatory or astrocyte responses, cerebral atrophy or 
reduced functional reserve. A study of experimentally induced ICH found worse neurological 
outcome and larger PHE volumes in 18 month compared to 3 month old rats(19).  However, a 
retrospective analysis of 219 consecutive ICH patients assessed with sequential CT failed to 
find any association of PHE volume and age(20).  Older age emerged as a predictor of a smaller 
EED72 in our study involving a much larger ICH cohort, which may suggest that older people 
have impaired, or delayed, inflammatory response in ICH(21).  
We found that lobar location of ICH was predictive of smaller EED72-0. The existing literature 
is conflicted in regards to haematoma location and PHE volume(22–24), which may be due to 
confounding and chance related to study design and sample size, as well as the inclusion of 
larger haematomas which may not be easily classified as deep or lobar. Moreover, no previous 
study has used EED as a measure of PHE which is relatively less dependent on haematoma 
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size and likely to provide a more reliable assessment of the association between ICH location 
and oedema by adjusting for haematoma volume. The capacity for water to diffuse through 
brain tissue can be driven by any change in the microstructure which alters diffusivity such as 
mechanical compression, membrane damage, inflammation, and shifts in water content in 
either the intra- or extra-cellular space. A potential biological explanation for higher EED in 
deep ICH is that deep haematomas are typically adjacent to densely packed white matter tracts.  
Myelin is a major diffusion barrier to water, a property that is exploited in diffusion 
tractography.  This may preferentially facilitate the movement of water along the direction of 
white matter tracts, allowing greater propagation of oedema than might be seen with a lobar 
haemorrhage surrounded by gray matter. Further studies using diffusion tensor MRI may help 
to test this hypothesis further.  Finally, although EED72-0 was not statistically associated with 
mortality, it had a large HR in the model and requires confirmation in a larger dataset.  
The presence of baseline IVH was also associated with a lower EED72-0. Although there is no 
clear explanation for this association, it may be that IVH leads to higher intraventricular 
pressure which may be transmitted to the brain parenchyma, reducing the production of 
perihaematomal oedema. Secondly, the presence of blood adjacent to the ventricular ependyma 
may alter the biological processes in the underlying brain parenchyma such that less oedema 
is generated over the first 72 h. For example, the inflammatory response may progress more 
quickly in the intraventricular space and ‘anti-inflammatory’ cytokines (e.g. interleukin-1 
receptor antagonist, transforming growth factor beta) associated with repair and recovery may 
be generated earlier, influencing the brain parenchyma adjacent to the ventricle. Further work 
in experimental models is needed to test these hypotheses. 
 
Although our study was strengthened by having a large, ethnically diverse (60% Caucasian, 
34% Asian) sample with robust measures of PHE, we acknowledge several limitations that 
includes the development of the EED parameter, which required the assumption of an ellipsoid-
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shaped haematoma and oedema, which is present in only 70% of patients(4). Peak PHE volume 
may have an independent effect on outcome in ICH(25), but we were unable to assess this in 
our cohort. Furthermore, our sample size was still small for examination of modest, but still 
clinically important, associations relevant to the serious disease of ICH. Finally, our cohort was 
younger and with a greater proportion of lobar ICH compared to population based studies(26), 
this may limit our study’s representativeness.  
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Conclusion 
We have previously shown that the use of EED as the outcome measure for PHE in clinical 
trials markedly reduces the sample size required.  We have now confirmed this in a much larger 
dataset and demonstrated that EED72-0 is significantly associated with mRS at 90 days. 
Although validation in prospective studies is desired, our study strengthens the case for the use 
of EED72-0 as a surrogate outcome measure for early phase clinical trials of anti-oedema 
treatments in ICH.  
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Tables and Figures  
 
Figure 1: Example of a CT scan demonstrating delineation of the region of perihaematomal 
oedema (PHE) (outlined in green) and ICH (outlined in red). The EED is the difference 
between the radius (re) of a sphere (shown in green) equal to the combined volume of PHE and 
ICH and the radius of a sphere (shown in red) equal to the volume of the ICH alone (rh) (12). 
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Figure 2: Box plots showing the relationship between oedema volume and haematoma 
volume, at baseline (A: r= 0.78, p< 0.001) and 72 hours (B: r= 0.80, p<0.001) and oedema 
extension distance and haematoma volume, at baseline (C: r= 0.35, p< 0.001) and 72 hours (D: 
r= 0.30, p<0.001).  
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Table 1: Population baseline characteristics.  SD= standard deviation, TIA= transient 
ischaemic attack, SBP= systolic blood pressure, NIHSS= National Institute of Health Stroke 
Score, IVH= intraventricular haemorrhage.  
 
Total 
N= 1028 
Cohort 
p-value VISTA 
N= 725 
INTERACT1 
N= 241 
MISTIE-II 
N= 62 
Mean age (SD) 64.7 (12.1) 65.6 (12.1) 62.7 (12.3) 62.5 (10.9) 0.002 
Male (%) 656 (63.8) 466 (64.3) 151 (62.7) 39 (62.9) 0.89 
Hypertension 
(%) 843 (82.0) 610 (84.1) 178 (73.9) 55 (88.7) 0.001 
Diabetes 
mellitus (%) 170 (16.5) 132 (18.2) 22 (9.1) 16 (25.8) <0.001 
Previous 
anticoagulation 
(%) 
10 (1.0) -  3 (1.2) 7 (11.3) <0.001 
Mean baseline 
SBP mmHg 
(SD) 
173.0 (37.0) 173.0 (39.0) 178.5 (30.0) 143.5 (30.0)* <0.001 
Median baseline 
NIHSS (IQR) 13.0 (9.0) 13.0 (8.0) 10.0 (10.0) 19.5 (7.0)* <0.001 
Median baseline 
haematoma 
volume cm3 
(IQR) 
13.7 (19.8) 14.6 (19.1) 9.5 (12.4) 39.0 (24.0) <0.001 
Median 72h 
haematoma 
volume  cm3 
(IQR) 
15.0 (22.9) 17.1 (25.8) 9.9 (12.6) 19.6 (30.3) <0.001 
Median baseline 
oedema volume 
cm3 (IQR) 
9.2 (12.9) 8.9 (12.3) 7.5 (9.1) 27.1 (20.8) <0.001 
Median 72h 
oedema volume 
cm3 (IQR) 
21.8 (27.8) 23.5 (30.9) 15.3 (21.4) 30.0 (16.4) <0.001 
Presence of IVH 
at baseline (%) 320 (31.1) 225 (31.0) 60 (24.9) 35 (56.5) 0.11 
Index 
haematoma 
location (%) 
     
Supratentorial 
lobar 159 (15.5) 113 (15.6) 22 (9.1) 24 (38.7) <0.001 Supratenorial 
deep 869 (84.5) 612 (84.4) 219 (90.9) 38 (61.3) 
*Recordings at randomization.  
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Table 2: Clinical trial sample size calculations using PHE as the primary outcome. Number of 
patients required in each arm of a clinical trial with difference in PHE between baseline and 72 
hours as the primary outcome, assuming α = 0.05 and either 80% or 90% power to detect a 
range of reductions in each measure. Calculations based on data from the conservative arms of 
VISTA, INTERACT1 and MISTIE-II. Mean (SD) for each measure were PHE volume (72-0), 
15.27 ml (18.78 ml); relative PHE (72-0), 0.86 ml (0.97 ml); EED72-0, 0.24 cm (0.18 cm). 
PHE= perihaematomal oedema, EED= oedema extension distance. 
 
 
 
 
 
 
 
 
 
 
Reduction 
in measure  
(%)(%) 
80% power 90% power 
PHE Vol 
(72-0) 
Relative 
PHE (72-0) EED72-0 
PHE Vol 
(72-0) 
Relative 
PHE (72-0) EED72-0 
5 9485 7988 3532 12698 10694 4728 
10 2374 1997 883 3179 2673 1182 
15 1056 888 392 1413 1188 525 
20 594 499 221 795 668 296 
25 380 320 141 508 428 189 
30 264 222 98 353 297 131 
35 194 163 72 260 218 96 
40 148 125 55 199 167 74 
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Table 3: Table describing baseline factors associated with (square root) EED72-0. EED= 
oedema extension distance, IVH= intraventricular haemorrhage.   
 
 
 
Predictor variable Coefficient P value Lower 95% CI Upper 95% CI 
Age -0.001 <0.001 -0.001 <-0.001 
Lobar haemorrhage (vs. 
deep haemorrhage) -0.018 0.018 -0.033 -0.003 
Baseline haematoma 
volume 0.001 <0.001 <0.001 0.001 
Presence of baseline 
IVH (vs. not) -0.016 0.003 -0.027 -0.006 
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Table 4: Results of testing for associations with mRS at 90d – ordinal regression model. CI= 
confidence interval, IVH= intraventricular haemorrhage 
 
 
 
 
 
  
Predictor 
variable Odds Ratio 
Standard 
error 
P 
value 
Lower 95% 
CI 
Higher 95% 
CI 
Male sex 0.78 0.09 0.035 0.61 0.98 
Age 1.05 0.006 <0.001 1.04 1.06 
Diabetes 1.65 0.27 0.002 1.20 2.29 
Antiplatelet 
therapy 1.70 0.30 0.003 1.20 2.41 
Anticoagulation 2.74 0.90 0.002 1.44 5.20 
Statin 0.74 0.15 0.124 0.50 1.09 
Lobar 
haemorrhage 0.59 0.11 0.003 0.41 0.84 
Haematoma 
volume 72 
hours 
1.04 0.004 <0.01 1.04 1.06 
Presence of 
IVH at 72 
hours 
2.68 0.34 <0.001 2.09 3.45 
EED72-0 1.96 0.67 0.049 1.00 3.82 
Online Supplement 
Supplementary Figure I: Flow diagram outlining patient exclusions.  
 
 
  
 
Supplementary Figure II: scatterplot depicting the relationship between EED72 and EED0. 
P= 0.53. EED= oedema extension distance.  
 
 
Supplementary Table I: Results of testing for associations with mortality – Cox regression 
model. EED= oedema extension distance, IVH= intraventricular haemorrhage.  
 
 
 
 
 
 
 
Predictor 
variable Hazard  Ratio 
Standard 
error P value 
Lower 95% 
CI 
Higher 95% 
CI 
Age 1.04 0.01 <0.001 1.03 1.06 
Male sex 1.72 0.36 0.009 1.14 2.60 
Antiplatelet 
therapy 1.97 0.41 0.001 1.31 2.97 
Presence of 
IVH at 72 
hours 
2.14 0.44 <0.001 1.43 3.20 
EED72-0 2.21 1.02 0.085 0.90 5.47 
Baseline 
haematoma 
volume 
1.03 0.003 <0.001 1.02 1.03 
Supplementary Table II: Sensitivity analysis of associations with mRS at 90d (ordinal 
regression model) in those without neurosurgical intervention. EED= oedema extension 
distance, IVH= intraventricular haemorrhage.  
 
 
 
 
Predictor 
variable Odds Ratio 
Standard 
error 
P 
value 
Lower 95% 
CI 
Higher 95% 
CI 
Male sex 0.76 0.09 0.026 0.59 0.97 
Age 1.05 0.006 <0.001 1.04 1.06 
Diabetes 1.53 0.26 0.012 1.10 2.14 
Antiplatelet 
therapy 1.61 0.30 0.011 1.11 2.32 
Anticoagulation 2.30 0.82 0.019 1.15 4.63 
Statin 0.68 0.14 0.065 0.45 1.02 
Lobar 
haemorrhage 0.60 0.12 0.009 0.41 0.88 
Haematoma 
volume 72 
hours 
1.05 0.004 <0.01 1.04 1.06 
Presence of 
IVH at 72 
hours 
2.48 0.33 <0.001 1.91 3.22 
EED72-0 1.95 0.69 0.060 0.97 3.92 
